Medical Devices: Page 138


  • Image attribution tooltip
    Brian Tucker
    Image attribution tooltip

    FDA clears Pentax duodenoscope with disposable part in bid to cut infection risk

    Center for Devices and Radiological Health Director Jeff Shuren called the clearance "another major step toward lowering the risk of infection among patients," and said duodenoscope safety is a top priority for the agency.

    By David Lim • Nov. 18, 2019
  • Edwards recalls Pascal valve guide sheath in Europe amid potential for embolizations

    A manufacturing problem resulting in damage to the inner lining of the sheath in fewer than 1% of devices prompted the recall. No adverse events were linked to the issue.

    By Nov. 18, 2019
  • the FDA Headquarters Explore the Trendline
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip
    Trendline

    Top 5 stories from MedTech Dive

    From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

    By MedTech Dive staff
  • Qiagen in talks with potential buyers amid weak results, restructuring

    The molecular test maker confirmed Friday it has received several non-binding indications of interest, days after Bloomberg reported Thermo Fisher was eyeing a takeout of Qiagen.

    By Nov. 18, 2019
  • In stents v. statin debate, analysts call potential impact of ISCHEMIA trial overhyped

    The study seemed to favor a conservative approach to treating stable heart disease. But many sell-side analysts called results expected, predicting they won't meaningfully hurt sales for device makers like Boston Scientific.

    By Maria Rachal • Nov. 18, 2019
  • Abiomed's Impella may be associated with higher costs, more adverse events than balloon therapy, studies find

    "In the long term, who knows how this will play out?" Jefferies analyst Raj Denhoy told MedTech Dive Monday morning amid a 10% drop in its share price. "In terms of the stock, it isn't great." 

    By Dana Elfin • Nov. 18, 2019
  • Titan Medical puts robot system on hold amid cash crisis

    CEO David McNally blamed the move on "inhospitable conditions in the equity capital markets," pledging the company will continue to attempt to secure financing.

    By David Lim • Nov. 15, 2019
  • FDA advisers: Metal implants need beefed up ingredient labels

    Industry representative Whitney Christian, a toxicologist at Medtronic, told the panel that medical device manufacturers support patients' and doctors' "right to know" what's in implants and are willing to work with FDA on the issue. 

    By Maria Rachal • Nov. 15, 2019
  • BioSig targets 9 installations of cardiac technology in 2020

    BioSig expects the rollout of PURE EP next year to generate its first revenues, allowing it to grow its sales team and enter Europe in 2021.

    By Nov. 15, 2019
  • Feds sue South Dakota surgeon, distributorships over alleged spinal implant kickbacks

    The suit comes amid a backdrop of growing fraud concerns related to physician-owned entities providing medical products to doctors. 

    By Dana Elfin • Nov. 14, 2019
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Axonics wins PMA for urinary indication in sacral neuromod, potentially tripling market

    The latest approval for overactive bladder positions the medtech to challenge Medtronic for dominance in the sacral neuromodulation market. Shares rose 16% in late morning trading.

    By Dana Elfin • Nov. 14, 2019
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA overhauls export certificate guidance after negative feedback

    AdvaMed said the draft suffered "from inaccuracies and omissions that FDA must correct." The final guidance provides more information on the appeals process and grounds for denials.

    By Nov. 14, 2019
  • FDA experts weigh evidence on patients' adverse reactions to common device metals

    Suggestions from speakers at Wednesday's advisory panel included conducting comparative effectiveness studies, bolstering the informed consent process and requiring more stringent adverse event reporting.

    By Maria Rachal • Nov. 13, 2019
  • Boston Scientific faces lower reimbursement despite White House lobbying bid

    In an Office of Management and Budget meeting days before release of CMS' hospital outpatient payment final rule, execs argued the change would deter doctors from a procedure using a device that could reduce opioid dependence.

    By David Lim • Nov. 13, 2019
  • Abbott names Robert Ford new CEO, ending Miles White's 21-year tenure in March

    The leadership handoff to Ford, an Abbott insider currently serving as COO, is seen as a continuation of current strategy, with Freestyle Libre, Mitraclip and Alinity driving core growth. 

    By Dana Elfin • Nov. 13, 2019
  • TransEnterix cuts 18% of staff, doesn't take questions from analysts

    The company will focus less on selling robotic surgery systems, newly appointed CEO Anthony Fernando told investors during its third quarter earnings call. Instead, he wants to expand use among existing customers.

    By Nov. 13, 2019
  • Eudamed 2-year delay doesn't mean free pass for manufacturers

    "The Eudamed project is expensive both in time and resources. It is not just an IT project, this is a change project," said Eudamed.eu CEO Richard Houlihan.

    By Dana Elfin • Nov. 12, 2019
  • Medtronic's Micra AV pacemaker meets study goals, submitted for FDA review

    The company wants to expand the transcatheter pacing system​ first approved in 2016 to patients with atrioventricular block, a condition marked by impaired electrical signals between the heart's upper and lower chambers.

    By Nov. 12, 2019
  • Establishment Labs sees 40% rise in breast implant sales, on track for $100M benchmark in 2020

    As it awaits U.S. marketing authorization, the Costa Rican medtech is expanding its direct sales force in Europe and Brazil amid a 45% year-to-date decline in Allergan's worldwide breast implant revenues.

    By Maria Rachal • Nov. 12, 2019
  • Life Spine, execs settle implants kickback case for nearly $6M

    The medtech said it had made significant progress strengthening its compliance program even before it began negotiations with the government.

    By Dana Elfin • Nov. 11, 2019
  • Wright Medical growth slowed in run-up to Stryker deal

    While Wright's Cartiva big toe treatment dragged on sales for a second straight quarter, Stryker expects the acquisition to bolster its broader extremities business, particularly in shoulder devices.

    By Nov. 11, 2019
  • Duodenoscope reprocessors' poor work conditions exacerbate infection problem, FDA panel says

    The advisory meeting followed FDA disclosing reports of three deaths, 45 patient infections and 159 cases of device contamination related to inadequate device reprocessing between October 2018 and March 2019.

    By David Lim • Nov. 8, 2019
  • In latest delay, time extended for experts to apply for MDR, IVDR panels

    Industry insiders said low compensation and a stringent conflict of interest policy may have discouraged experts from applying to the panels. Notified bodies must consult with the panels before clearing certain high-risk devices.

    By Dana Elfin • Nov. 8, 2019
  • Medtronic reveals high-risk cyber vulnerability in electrosurgical generators

    The Department of Homeland Security rated the vulnerability, which could be exploited remotely by a low-skilled hacker, a 9.8 on a 10-point risk scale.

    By Nov. 8, 2019
  • Deep Dive

    Ethylene oxide plant closures put US on 'cusp of a major medical logistical failure'

    FDA should consider asking HHS Secretary Alex Azar to declare a public health emergency and override state legislation to get sterilization plants back online, one advisory panel member said.

    By David Lim • Nov. 8, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare overpays for certain orthotic devices, OIG finds

    Medicare and beneficiaries reportedly paid $341.7 million more than other payers for certain orthotic devices, building on prior investigations' findings that CMS has overpaid for services like radiation and sleep studies.

    By Nov. 7, 2019